Switching from Mounjaro to Wegovy: what the science says

What's this video probably claiming?

Based on the caption, @shrinkingmom is sharing a first-person account of switching from tirzepatide (Mounjaro) to semaglutide (Wegovy) and reporting that the drugs felt "very similar" in week one. She also mentions fatigue, which she attributes to the back-to-school period rather than the medication, and describes taking her first dose at night to sleep through any immediate side effects. These are exactly the kinds of anecdotal switching tips that rack up views because real clinical guidance on mid-treatment drug switches is sparse and confusing. The implicit claim here is that the two drugs are roughly interchangeable in experience and effect, and that timing your dose to coincide with sleep is a reasonable side-effect management strategy. Neither of those claims is straightforwardly wrong, but neither is quite as simple as a one-week personal account can capture.

What does the science actually show?

Tirzepatide and semaglutide are not the same drug. Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a selective GLP-1 agonist. That distinction matters clinically. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15 mg achieving mean weight loss of 20.9% body weight over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg achieving 14.9% over 68 weeks. Head-to-head data is limited, but a 2023 retrospective analysis by Bergmann et al. in the Journal of Clinical Endocrinology and Metabolism found tirzepatide users lost significantly more weight than semaglutide users at 12 months in a real-world sample of 18,386 patients. On nausea and GI side effects, the profiles overlap substantially, which may explain the creator's "very similar" perception in week one, but the mechanisms and long-term metabolic effects are meaningfully different.

Where does the social media noise diverge from clinical reality?

The "felt similar" framing is one of the most common and potentially misleading tropes in GLP-1 social media content. One week at a starting dose tells you almost nothing about how two drugs will perform differently over months. Both Wegovy and Mounjaro use slow titration schedules, so a week-one comparison is essentially comparing the lowest rungs of two different ladders. The nighttime dosing tip is widely shared on TikTok and appears to help some people tolerate initial GI symptoms, but it has not been evaluated in controlled trials. Timing recommendations in the official prescribing information for both drugs do not specify a preferred time of day. The fatigue observation is also genuinely unverifiable from a caption alone. Semaglutide has been associated with fatigue as a reported adverse event in trials, but separating medication effect from life circumstances, like a household routine changing with kids returning to school, is something a clinical trial design handles and a TikTok video cannot.

What should you actually know?

If you are considering switching between these medications, the conversation needs to happen with a prescribing clinician, not a comment section. There is no standardized, evidence-based switching protocol published in major guidelines as of mid-2024. Clinicians typically restart at the lowest titration dose when switching agents, which means short-term weight loss may stall or side effects may feel amplified. Patients switching from tirzepatide to semaglutide should also be aware that the efficacy ceiling may be lower based on available trial data. On the nighttime dosing point, it is a reasonable practical strategy some clinicians suggest informally, but it should not be treated as a validated clinical recommendation. The broader issue with this genre of content is that individual experience, even one shared in good faith, gets treated as transferable advice. GLP-1 response varies substantially by individual, dose, duration, and metabolic baseline.